For patients with metastatic NSCLC with sensitizing EGFR mutations who progress on first line TKI therapy who do not have evidence of T790M mutation, do you add cetuximab (with afatinib) or bevacizumab (with erlotinib) at progression?

Treatment paradigms have altered considerably over the past two years for patients with EGFR mutations There are now three approved TKIs (afatinib, gefitinib, erlotinb) that all have demonstrated improved outcomes when compared to chemotherapy. In addition, the addition of bevacizumab to erlotinib i...